Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections.
Br J Clin Pharmacol
; 86(11): 2319-2324, 2020 11.
Article
en En
| MEDLINE
| ID: mdl-32330996
ABSTRACT
For management of osteoarticular infections, rifampicin appears to be the key antibiotic. We aimed to evaluate the actual rifampicin dosing regimens using a population pharmacokinetic model of rifampicin in patients with osteoarticular infections. A Monte Carlo simulation study was performed to simulate steady-state plasma concentrations for 1000 randomly sampled subjects using a total daily dose between 600 and 1200 mg (600 and 900 mg once daily, 450 and 600 mg twice daily, or 300 mg 3 times daily). When rifampicin was administered with fusidic acid, the pharmacokinetic/pharmacodynamic (PK/PD) target (area under the curve/minimum inhibitory concentration ≥952) was achieved with all tested dosing regimen, except 600 mg once daily for Staphylococcus epidermidis infections. Without coadministration of fusidic acid, none of tested dosing regimens achieved this PK/PD target. Most recommended drug-dosing regimens allow attaining the fixed area under the curve/minimum inhibitory concentration target for Staphylococcus aureus and coagulase-negative staphylococcal osteoarticular infections. In future studies, PK/PD target for osteoarticular infections in human should also be confirmed.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Rifampin
/
Infecciones Estafilocócicas
Tipo de estudio:
Guideline
/
Health_economic_evaluation
/
Prognostic_studies
Límite:
Adult
/
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article